Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study

Ibrahim, Lobna, DiazGranados, Nancy, Franco-Chaves, Jose, Brutsche, Nancy, Henter, Ioline D, Kronstein, Phillip, Moaddel, Ruin, Wainer, Irving +3 more·2012·Neuropsychopharmacology
DOI 10.1038/npp.2011.338

Cited by (309)

Items 301–309 of 309

  1. Ketamine/esketamine for treatment-resistant depression
    Sina Nikayin, Gerard Sanacora · 2022 · Elsevier eBooks
  2. Additional file 1 of Optimizing the use of ketamine to reduce chronic postsurgical pain in women undergoing mastectomy for oncologic indication: study protocol for the KALPAS multicenter randomized controlled trial
    Wang, Jing, Lisa Doan, Deborah Axelrod, Rotrosen, John, Binhuan Wang, Park, Hyung G., Robert Randolph Edwards, Michele Curatolo, Carina Jackman, Raven Perez · 2024 · Figshare
  3. Modulatory effects of ketamine on EEG source-based resting state connectivity in treatment resistant depression
    Ty Lees, Jason N. Scott, Brian W. Boyle, Shiba M. Esfand, Samantha R. Linton, Courtney Miller, Mohan Li, Sarah E. Woronko, Rebecca Dunayev, Mario Bogdanov et al. · 2026 · Translational Psychiatry
  4. Rôle des connexines 43 astrocytaires : une étude fonctionnelle dans un modèle murin de dépression basé sur le stress chronique
    Benjamin Portal · 2019 · theses.fr (ABES)
  5. Comparison of average time-to-relapse following ECT versus ketamine – A systematic review
    Minna Chang, Allan Hunter Young, Mário F. Juruena · 2026 · Journal of Psychopharmacology
  6. Modulation of early non-rapid eye movement slow wave activity by ketamine in treatment-resistant depression
    Nadia S. Hejazi, Mina Kheirkhah, Brady A. Riedner, Qiaoping Yuan, Parth Chholak, Reza Momenan, Gregory H. Jones, David Goldman, Carlos A. Zarate · 2026 · Neuropsychopharmacology
  7. Augmentation strategies for intravenous ketamine in treatment-resistant depression: A systematic review and meta-analysis
    Reinhard Janssen‐Aguilar, Jithin Thekkelkuthiyathottil Joseph, Huda F. Al-Shamali, Kaija Taylor, Zixu Zhao, Qiaowei Lin, Wendy Lou, Yanbo Zhang, Andrew Greenshaw, Walter Dunn et al. · 2026 · Journal of Affective Disorders
  8. Discovery of Potent, Selective, and Orally Bioavailable GluN2B-NMDA Receptor Antagonists for the Treatment of Depression
    Qian Tang, Jianquan Feng, Chunyang Hu, Jie Feng, Ding Du · 2026 · European Journal of Medicinal Chemistry
  9. Oral Esketamine Maintenance Treatment for Treatment‐Resistant Depression: Clinical Outcomes During an Off‐Label Treatment Program
    Sanne Y. Smith-Apeldoorn, Jolien K. E. Veraart, Jan Spijker, Annemarie van der Meij, Jeanine Kamphuis, Robert A. Schoevers · 2026 · Depression and Anxiety